Sarepta's Gene Therapy Just Got the Scariest Label in Medicine
Sarepta's flagship Duchenne gene therapy just earned the FDA's most severe safety warning after fatal liver failures, and the company is cutting 36% of its workforce. What happens when gene therapy's biggest commercial success story hits a wall?
The FDA's Nuclear Option
In the world of drug labels, a black box warning is the equivalent of a skull and crossbones on a bottle of poison. It's the most severe safety alert the FDA can slap on an approved medicine, and it's now sitting at the top of the prescribing information for Elevidys, Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy.
The warning is for acute serious liver injury and acute liver failure, including cases that were life-threatening and fatal. Sarepta also announced it's laying off roughly 500 employees, about 36% of its workforce. For a company that once stood as the poster child of gene therapy ambition, this is a brutal one-two punch.
What Went Wrong Inside the Liver
Elevidys (delandistrogene moxeparvovec, if you enjoy tongue twisters) was supposed to be a breakthrough. It's a one-time gene therapy designed to deliver a shortened version of the dystrophin gene to boys with Duchenne muscular dystrophy, a devastating disease that progressively destroys muscle function. Think of it as installing a software patch for a critical gene that's either missing or broken.
But the delivery vehicle, an adeno-associated virus (AAV), doesn't always play nice with the body. The FDA reported two fatal cases of acute liver failure in non-ambulatory pediatric patients (kids who had already lost the ability to walk) after receiving Elevidys. Liver injury typically showed up within about eight weeks of treatment, with dramatically elevated liver enzymes and hospitalizations in the worst cases.
The agency didn't stop at the black box warning either. It pulled the non-ambulatory indication entirely, meaning Elevidys can now only be used in patients who are still ambulatory (able to walk). That's a significant shrink of the eligible patient pool. Doctors are also now required to run liver function tests before treatment and monitor weekly for the first three months afterward.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The financial fallout tells the story in numbers. Elevidys generated $898.7 million in full-year 2025 revenue, which sounds impressive until you look at the quarterly trajectory. Sales went from $375 million in Q1 2025 to just $110.4 million in Q4 2025, a quarter-over-quarter decline that looks like a ski slope.
By Q2 2026, things got worse. Total company revenue dropped to $401.3 million, down from $611.1 million in the same period a year earlier. The culprit: far fewer patients qualifying for treatment after the label was narrowed to ambulatory-only. Sarepta suspended shipments to non-ambulatory patients in the U.S. back in June 2025, and the revenue impact has been cascading ever since.
Management has maintained a $500 million annual sales floor for Elevidys in 2026, along with total net product revenue guidance of $1.2 billion to $1.3 billion. But Wall Street isn't exactly brimming with confidence. The stock was trading around $21 in late August, and analyst sentiment is split between cautious holds and outright sells, with price targets ranging from $13 to $25.
Cutting Deep to Stay Alive
The 500-person layoff isn't just belt-tightening; it's a full-blown strategic pivot. Sarepta said the restructuring should save about $400 million annually, broken down into roughly $120 million from the workforce cuts and $300 million from pausing pipeline programs.
And the programs getting paused are notable. Most of Sarepta's limb-girdle muscular dystrophy gene therapy work is being shelved. The company is redirecting resources toward what it considers higher-value bets, with a particular emphasis on siRNA-based programs (small interfering RNA, a different technology that silences disease-causing genes rather than replacing them).
The subtext is hard to miss: Sarepta is hedging against the possibility that its AAV gene therapy platform may face structural challenges beyond Duchenne. For programs the company can no longer fund directly, it's actively looking for partners or strategic alternatives. When a biotech starts "seeking strategic alternatives" for its own programs, that's corporate-speak for "please, someone take these off our hands."
The Bigger Picture for Gene Therapy
Sarepta's troubles aren't happening in a vacuum. AAV-based gene therapies across the industry have faced persistent safety questions around liver toxicity, and these two deaths add to a growing body of evidence that the delivery technology carries real risks, especially in sicker patients.
For the broader Duchenne landscape, the competitive picture is shifting. REGENXBIO has its RGX-202 program heading toward a pivotal readout in 2026. Solid Biosciences continues testing its own gene therapy candidates. Meanwhile, the standard of care still relies heavily on corticosteroids and mutation-specific exon-skipping drugs (therapies that help cells "skip" over the faulty part of the gene to produce a partially functional protein). But each exon-skipping drug only works for a subset of patients; exon 51 skipping, for example, covers roughly 13% of the DMD population.
That limited coverage is exactly why a one-time gene therapy like Elevidys generated so much excitement in the first place. It was supposed to work regardless of the specific mutation. The black box warning doesn't kill that promise, but it puts a very large asterisk next to it.
What Comes Next
Sarepta isn't dead, but it's operating in survival mode. The company still has its PMO exon-skipping franchise generating nearly a billion dollars a year ($965.6 million in 2025), and it's pursuing traditional FDA approval for Amondys 45 and Vyondys 53. Beyond Duchenne, pipeline catalysts include Phase 1/2 data readouts in myotonic dystrophy type 1 and facioscapulohumeral dystrophy in the second half of 2026, plus early work on SRP-1005 for Huntington's disease.
But the core question looming over the company is whether gene therapy's biggest commercial success story just hit an irreversible wall, or whether this is a painful but manageable setback. Key Elevidys clinical data (Cohort 8 twelve-week results) have been pushed into Q1 2027, which means investors will be waiting a while for clarity.
For now, Sarepta is a smaller, leaner, more cautious version of itself. The gene therapy revolution it helped pioneer isn't over, but the company just learned one of medicine's oldest lessons the hard way: delivering a gene is the easy part. Making sure the body doesn't revolt against the delivery is where things get complicated.
Clinical & Regulatory4 min read
The First New Blood Cancer Drug in 30 Years Just Got the Green Light
For nearly 30 years, patients with essential thrombocythemia had zero new FDA-approved treatments. PharmaEssentia's BESREMi just broke that streak with trial results that crushed the competition seven to one.
